Merck KGaA Articles
Corporate R&D investment in 2008: a global increase with EU companies leading USA and Japan; Pharma/biotech top sectors
16 November 2009
Merck & Co remains confident in Zetia and Vytorin, despite studying questioning the drugs
16 November 2009
Former S-P chief Fred Hassan joins Bausch & Lomb board of directors
13 November 2009
Merck KgaA unit and Isofol in deal for Modufolin in oncology
12 November 2009
Bristol-Myers Squibb gains rights to Alder’s rheumatoid arthritis biologic for up to $1 billion
11 November 2009
Targeted agents will drive gastric cancer drug market to nearly $1.5 billion in 2018
5 November 2009
Merck & Co - now world’s No 2 drugmaker - upbeat about new operation post Schering-Plough merger; but what about J&J?
5 November 2009
With completion of Merck & Co/Schering-Plough merger, Haruo Naito confirmed as new president of IFPMA
4 November 2009
One time gain triples Merck & Co’s 3rd quarter 2009 earnings, beating forecasts; EU clears S-P deal
23 October 2009
UK’s NICE won’t fund GSK’s breast cancer drug Tyverb; USA’s CDC backs Cervarix and Merck & Co’s Gardasil for boys
22 October 2009
Malaysian govt encouraging biotech sector of pharma market
22 October 2009
Galapagos expands metabolic disease with Merck & Co; will now get more than 400 million euros
15 October 2009
Merck KGaA acquires Indian bioscience company Bagalore Genei
14 October 2009
GSK in 1.5 billion-euro deal with Brazil for pneumococcal vaccine; first Cervarix death reported
29 September 2009
Merck & Co gets exclusive US rights to CSL’s Afluria season flu vaccine
29 September 2009
ECCO/ESMO: new data show Merck Serono ’s Erbitux extends survival in colorectal and lung cancers
28 September 2009
BIO-Europe 2009: an opportunity to hunt for deals
25 September 2009
Merck KGaA hit by disappointing Erbitux results from COIN study
24 September 2009
Wellcome Trust and Merck & Co invest £$130 million to launch first-of-its-kind JV to develop affordable vaccines
19 September 2009
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will erode $8.2 billion in US and European sales in 2018
17 September 2009
EU approves expanded use of Merck & Co’s Isentress in adult patients with HIV-1 Infection
16 September 2009
First federal trial of Merck & Co’s Fosamax declared a “mistrial”
14 September 2009
Merck & Co updates on telcagepant and drops MK-2003 program
11 September 2009
US FDA reviews supports GlaxoSmithKline’s Cervarix and Merck & Co’s Gardasil in males
7 September 2009
UK’s NICE recommends Merck KGaA’s Erbitux cetuximab for the first-line treatment of metastatic colorectal cancer
26 August 2009
Merck wins Singulair patent infringement law suit with Teva
20 August 2009
Indian patent law changes will benefit Pharma multinationals
19 August 2009
Schering-Plough gets US approval for Saphris
17 August 2009
New top team at Takeda UK
17 August 2009
Elan appoints Renee Tannenbaum CCO
4 June 2009
Stock Commentary - Europe - week to June 1, 2009
4 June 2009
UK's NICE OKs Merck KGaA's Erbitux for mCRC
2 June 2009
Merck & Co's Emend 76.2% effective in CINV
1 June 2009
Tentative FDA OK for Mylan's generic Singulair
29 May 2009
J&J continues opposition to Merck/S-P merger
28 May 2009
Mylan to enforce generics presence in Spain
21 May 2009
BMJ: lymphatic filiarisis could be on way out
21 May 2009
Merck & Co to roll out Tredaptive by 3rd qtr
20 May 2009
Merck Serono pulls out of MediCult bid
19 May 2009
BMJ: lymphatic filiarisis could be on way out
15 May 2009
Stock Commentary - Europe - week to may 11, 2009
14 May 2009
Safinamide enters Ph III SETTLE trial
11 May 2009
Sales up by 84% cut loss for ZymoGenetics
8 May 2009
Evotec buys Sumit Zebrafish operations
8 May 2009
German Merck cancer drug may treat MS
1 May 2009
Stock Commentary - New York week to April 27, 2009
30 April 2009
EVM meets EC and EMEA over swine flu
30 April 2009
Merck KGaA's 1st-qtr profit tumbles 76.3% to 56.7M euros on lower liquid crystal sales
27 April 2009
Merck & Co signs performance-based contract with CIGNA
24 April 2009
CHMP meeting sees good news for AZ, but not for Teva
24 April 2009
Merck Serono launches Kuvan in Europe
23 April 2009
Medarex in up to $225M C. diff deal with Merck & Co
22 April 2009
Merck & Co to team with Galapagos in195M-euro deal
22 April 2009
Drugmakers spent $3M in Vermont
21 April 2009
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
